Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review

被引:40
作者
Cherny, Nathan I. [1 ]
Abernethy, Amy P.
Strasser, Florian
Sapir, Rama
Currow, David
Zafar, S. Yousuf
机构
[1] Shaare Zedek Med Ctr, Dept Med Oncol, Canc Pain & Palliat Med Serv, Canc Pain & Palliat Med Unit, IL-91031 Jerusalem, Israel
关键词
CELL LUNG-CANCER; QUALITY-OF-LIFE; EVIDENCE-BASED RECOMMENDATIONS; METASTATIC COLORECTAL-CANCER; PHASE-III TRIAL; INTERLEUKIN-2 PLUS MELATONIN; PROSPECTIVE RANDOMIZED-TRIAL; PREVIOUSLY TREATED PATIENTS; PINEAL HORMONE MELATONIN; PALLIATIVE CARE;
D O I
10.1200/JCO.2009.21.9592
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To systematically review the best supportive care (BSC) literature and to evaluate the ethical and methodologic validity issues by using widely acknowledged criteria. Methods Two search strings that included both cancer and supportive as terms (with random article type, or review or meta-analysis) explored databases from 1966 to 2008. Citations, abstracts, and papers were reviewed for inclusion criteria, and relevant data were extracted by two independent researchers. Data were validated for accuracy. Ethical and methodologic validity were evaluated by using the criteria derived from the Helsinki Requirements of the WMA; CONSORT statements for the evaluation of reports of randomized, controlled trials; and the universal requirements for ethical clinical research. Results Forty-three published papers were identified that described 32 studies, 20 of which incorporated the design of treatment plus supportive care (SC) versus SC alone, and 12 of which incorporated the design of treatment versus SC. Most of the studies had poor compliance to critical Helsinki requirements, to methodologic precautions derived from the CONSORT statement for studies involving a nonpharmacologic arm, and to four of seven universal requirements for ethical clinical research. Conclusion Lack of rigor in BSC studies has contributed to a generation of research with widespread ethical and methodologic shortcomings. Ad hoc SC and lack of standardization of SC delivery may be sources of systematic bias or error in BSC trials. Rectifying these shortcomings in future studies demands greater vigilance toward these issues by researchers, institutional review boards, editors, and peer reviewers. Given the prevalence of overlooked problems that are later identified, currently open BSC studies should be reevaluated by institutional review boards and researchers to check for ethical and methodologic validity, and identified shortcomings should be addressed.
引用
收藏
页码:5476 / 5486
页数:11
相关论文
共 136 条
[11]   Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: Explanation and elaboration [J].
Boutron, Isabelle ;
Moher, David ;
Altman, Douglas G. ;
Schulz, Kenneth F. ;
Ravaud, Philippe .
ANNALS OF INTERNAL MEDICINE, 2008, 148 (04) :295-309
[12]   Palliative care as an International human right [J].
Brennan, Frank .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2007, 33 (05) :494-499
[13]   Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial [J].
Brodowicz, T ;
Krzakowski, M ;
Zwitter, M ;
Tzekova, V ;
Ramlau, R ;
Ghilezan, N ;
Ciuleanuf, T ;
Cucevic, B ;
Gyurkovits, K ;
Ulsperger, E ;
Jassem, J ;
Grgic, M ;
Pinar, S ;
Szilasi, M ;
Wiltschke, C ;
Wagnerova, M ;
Oskina, N ;
Soldatenkova, V ;
Zielinski, C ;
Wenczl, M .
LUNG CANCER, 2006, 52 (02) :155-163
[14]   Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer [J].
Brown, J ;
Thorpe, H ;
Napp, V ;
Fairlamb, DJ ;
Gower, NH ;
Milroy, R ;
Parmar, MKB ;
Rudd, RM ;
Spiro, SG ;
Stephens, RJ ;
Waller, D ;
West, P ;
Peake, MD .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7417-7427
[15]  
BUCCHERI GF, 1989, CANCER-AM CANCER SOC, V63, P428, DOI 10.1002/1097-0142(19890201)63:3<428::AID-CNCR2820630305>3.0.CO
[16]  
2-V
[17]  
Buss MK, 2005, J CLIN ONCOL, V23, p737S
[18]   CISPLATIN CYCLOPHOSPHAMIDE MITOMYCIN COMBINATION CHEMOTHERAPY WITH SUPPORTIVE CARE VERSUS SUPPORTIVE CARE ALONE FOR TREATMENT OF METASTATIC NON-SMALL-CELL LUNG-CANCER [J].
CARTEI, G ;
CARTEI, F ;
CANTONE, A ;
CAUSARANO, D ;
GENCO, G ;
TOBALDIN, A ;
INTERLANDI, G ;
GIRALDI, T .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10) :794-800
[19]   A RANDOMIZED TRIAL OF OCTREOTIDE VS BEST SUPPORTIVE CARE ONLY IN ADVANCED GASTROINTESTINAL CANCER-PATIENTS REFRACTORY TO CHEMOTHERAPY [J].
CASCINU, S ;
DELFERRO, E ;
CATALANO, G .
BRITISH JOURNAL OF CANCER, 1995, 71 (01) :97-101
[20]   NON SMALL CELL LUNG-CANCER (NSCLC) - A PROSPECTIVE RANDOMIZED TRIAL WITH ALTERNATING CHEMOTHERAPY CEP/MEC' VERSUS NO TREATMENT [J].
CELLERINO, R ;
TUMMARELLO, D ;
PORFIRI, E ;
GUIDI, F ;
ISIDORI, P ;
RASPUGLI, M ;
BISCOTTINI, B ;
FATATI, G .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (12) :1839-1843